-+ 0.00%
-+ 0.00%
-+ 0.00%

Novocure says Phase 3 TRIDENT glioblastoma trial misses overall survival endpoint for earlier TTFields use

PUBT·06/18/2026 11:00:55
Listen to the news
Novocure says Phase 3 TRIDENT glioblastoma trial misses overall survival endpoint for earlier TTFields use
  • Novocure released topline results from the Phase 3 TRIDENT trial testing earlier initiation of Tumor Treating Fields in newly diagnosed glioblastoma.
  • Results were announced now, with additional analyses set for future presentation.
  • The study missed its primary goal, showing no clear survival advantage from starting the device during chemoradiation versus later use.
  • Management highlighted feasibility and tolerability for earlier use, with no new safety concerns reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260618609714) on June 18, 2026, and is solely responsible for the information contained therein.